课题基金 / 基金详情

IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS

IMMORTALIZATION OF SV40-TRANSFORMED HUMAN CELLS
SV40 转化人类细胞的永生化
批准号:
3115384
负责人:
HARVEY L OZER
金额:
$27.8万
依托单位国家:
美国
项目类别:
财政年份:
1988
资助国家:
美国
项目状态:
已结题
起止时间:
1988-12-01 至 1992-08-31

项目摘要

项目成果

HARVEY L OZER的其他基金

相似基金

相关文献

中文摘要
翻译
来自正常组织的人类二倍体细胞经历了一个特征 细胞培养中的生长模式,以非复制阶段结束, 最后,细胞死亡。细胞衰老的模型已经被开发出来 建议将这种模式与生物体在体内的行为相类似; 因此,“衰老”一词应运而生。人二倍体成纤维细胞(HF) 在体外被致癌DNA病毒SV40感染的人被发现 克服这一现象。我们发现了一株HF的克隆性分离物 SV40(svori-)原核缺陷突变体的转化 早期区域允许以异常高的速度分离永生化细胞 频率几种这样的克隆个体永生化HF的分析 将进行转化以确定可能的共同基因 改装。此外,我们还建议研究一系列独立的HF SV40来源缺陷突变体转化的研究 温度敏感型T抗原(ts A突变体)用于评估可能的基础 SV40在连续细胞启动和维持中的作用 紧张。
英文摘要
Human diploid cells derived from normal tissue undergo a characteristic pattern of growth in cell culture, ending with a non-replicative phase and, finally, cell death. Models of cellular aging have been developed which suggest analogy between this pattern and behavior of the organism in vivo; hence, the term "senescence". Human diploid fibroblasts (HF) which had been infected in vitro by the oncogenic DNA virus SV40 have been found to overcome this phenomenon. We have found that a clonal isolate of a HF transformed by an origin-defective mutant of SV40 (SVori-) with an intact early region permits isolation of immortalized cells at an unusually high frequency. Analysis of several such immortalized HF from individual cloned transformants will be performed to identify possible common genetic alterations. Further, we propose to study a series of independent HF transformed by origin-defective mutants of SV40 with a temperature-sensitive T antigen (ts A mutants) to assess possible bases for the role of SV40 in the initiation and maintenance of a continuous cell strain.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Interdisciplinary Training Program in Cancer Research
Interdisciplinary Training Program in Cancer Research
Interdisciplinary Training Program in Cancer Research
  • 批准号:
    8701009
  • 项目类别:
  • 资助金额:
    $6.57万
  • 财政年份:
    2010
  • 负责人:
    HARVEY L OZER
  • 依托单位:
Interdisciplinary Training Program in Cancer Research
海外基金